KRYSTAL BIOTECH INC. - COMMON STOCK

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

29 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

26 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

19 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

14 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

12 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

01 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

29 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

15 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021

09 Sep 2021 08:00:02 By Nasdaq GlobeNewswire

Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 16:31:00 By Nasdaq GlobeNewswire

Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress

09 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis

01 Jul 2021 16:15:00 By Nasdaq GlobeNewswire

Krystal Biotech to Participate in Upcoming Investor Conferences

03 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress

10 May 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Appoints Andy Orth as Chief Commercial Officer

03 May 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT

27 Apr 2021 16:35:00 By Nasdaq GlobeNewswire

Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB

26 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline

19 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

30 Mar 2021 08:00:02 By Nasdaq GlobeNewswire